Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy

References

• VisschedijkJvan de BroekJEggensHLeverPvan BeersSKlatserPMycobacterium leprae – millennium resistant! Leprosy control on the threshold of a new eraTrop Med Int Health20005638839910929137
   PubMed Web of Science ®Google Scholar
• JacobJTFranco-ParedesCThe stigmatization of leprosy in India and its impact on future approaches to elimination and controlPLoS Negl Trop Dis200821e11318235845
   PubMed Web of Science ®Google Scholar
• CrossHInterventions to address the stigma associated with leprosy: a perspective on the issuesPsychol Health Med200611336737317130073
   PubMedGoogle Scholar
• RidleyDSJoplingWHClassification of leprosy according to immunity. A five-group systemInt J Lepr Other Mycobact Dis19663432552735950347
   PubMedGoogle Scholar
• ScollardDMClassification of leprosy: a full color spectrum, or black and white?Int J Lepr Other Mycobact Dis200472216616815301586
   PubMedGoogle Scholar
• WHOGlobal leprosy situation, 2010Wkly Epidemiol Rec2010853533734820830851
   PubMedGoogle Scholar
• Global leprosy update, 2014: need for early case detectionWkly Epidemiol Rec2015903646147426343055
   PubMedGoogle Scholar
• BakkerMIHattaMKwenangARisk factors for developing leprosy – a population-based cohort study in IndonesiaLepr Rev2006771486116715690
   PubMed Web of Science ®Google Scholar
• MoetFJPahanDSchuringRPOskamLRichardusJHPhysical distance, genetic relationship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosyJ Infect Dis2006193334635316388481
   PubMed Web of Science ®Google Scholar
• GoulartIMBernardes SouzaDOMarquesCRPimentaVLGoncalvesMAGoulartLRRisk and protective factors for leprosy development determined by epidemiological surveillance of household contactsClin Vaccine Immunol200815110110517989339
   PubMedGoogle Scholar
• BakkerMIHattaMKwenangAKlatserPROskamLEpidemiology of leprosy on five isolated islands in the Flores Sea, IndonesiaTrop Med Int Health20027978078712225510
   PubMed Web of Science ®Google Scholar
• BrookCEBeauclairRNgwenyaOSpatial heterogeneity in projected leprosy trends in IndiaParasit Vectors2015854226490137
   PubMed Web of Science ®Google Scholar
• SalgadoCGFerreiraDVFradeMAGuimarães LdeSda SilvaMBBarretoJGHigh anti-phenolic glycolipid-I IgM titers and hidden leprosy cases, Amazon regionEmerg Infect Dis201218588989022515845
   PubMed Web of Science ®Google Scholar
• BarretoJGGuimaraes LdeSFradeMARosaPSSalgadoCGHigh rates of undiagnosed leprosy and subclinical infection amongst school children in the Amazon RegionMem Inst Oswaldo Cruz2012107Suppl 1606723283455
   PubMed Web of Science ®Google Scholar
• SmithWCvan BrakelWGillisTSaundersonPRichardusJHThe missing millions: a threat to the elimination of leprosyPLoS Negl Trop Dis201594e000365825905706
   PubMed Web of Science ®Google Scholar
• JobCKJayakumarJKearneyMGillisTPTransmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCRAm J Trop Med Hyg200878351852118337353
   PubMed Web of Science ®Google Scholar
• WeddellGPalmerEThe pathogenesis of leprosy. An experimental approachLepr Rev196334576113999438
   PubMedGoogle Scholar
• JobCKJayakumarJAschhoffM“Large numbers” of Mycobacterium leprae are discharged from the intact skin of lepromatous patients; a preliminary reportInt J Lepr Other Mycobact Dis199967216416710472371
   PubMedGoogle Scholar
• ShepardCCAcid-fast bacilli in nasal excretions in leprosy, and results of inoculation of miceAm J Hyg19607114715714445823
   PubMed Web of Science ®Google Scholar
• PedleyJCThe nasal mucus in leprosyLepr Rev197344133354584261
   PubMedGoogle Scholar
• Naves MdeMRibeiroFAPatrocinioLGPatrocinioJAFleuryRNGoulartIMBacterial load in the nose and its correlation to the immune response in leprosy patientsLepr Rev2013841859123741885
   PubMed Web of Science ®Google Scholar
• ReesRJMcDougallACAirborne infection with Mycobacterium leprae in miceJ Med Microbiol19771016368320339
   PubMed Web of Science ®Google Scholar
• AraujoSLobatoJReis EdeMUnveiling healthy carriers and subclinical infections among household contacts of leprosy patients who play potential roles in the disease chain of transmissionMem Inst Oswaldo Cruz2012107Suppl 1555923283454
   PubMed Web of Science ®Google Scholar
• ShepardCCLevyLFasalPRapid bactericidal effect of rifampin on Mycobacterium lepraeAm J Trop Med Hyg19722144464494559066
   PubMed Web of Science ®Google Scholar
• ShepardCCLevyLFasalPFurther experience with the rapid bactericidal effect of rifampin on Mycobacterium lepraeAm J Trop Med Hyg1974236112011244611256
   PubMed Web of Science ®Google Scholar
• GrossetJHGuelpa-LaurasCCBobinPStudy of 39 documented relapses of multibacillary leprosy after treatment with rifampinInt J Lepr Other Mycobact Dis19895736076142674301
   PubMedGoogle Scholar
• WilliamsDLGillisTPMolecular detection of drug resistance in Mycobacterium lepraeLepr Rev200475211813015282962
   PubMed Web of Science ®Google Scholar
• MatsuokaMBudiawanTAyeKSThe frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the PhilippinesLepr Rev200778434335218309708
   PubMed Web of Science ®Google Scholar
• MatsuokaMKashiwabaraYNamisatoMA Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacinInt J Lepr Other Mycobact Dis200068445245511332288
   PubMedGoogle Scholar
• ManjunathaUHLahiriRRandhawaBDowdCSKrahenbuhlJLBarryCE3rdMycobacterium leprae is naturally resistant to PA-824Antimicrob Agents Chemother200650103350335417005816
   PubMed Web of Science ®Google Scholar
• YouEYKangTJKimSKLeeSBChaeGTMutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in KoreaJ Infect200550161115603834
   PubMed Web of Science ®Google Scholar
• WHOMeeting on Sentinel Surveillance for Drug Resistance in LeprosyGenevaWorld Health Organization2011
   Google Scholar
• JiBJametPSowSPeraniEGTraoreIGrossetJHHigh relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeksAntimicrob Agents Chemother1997419195319569303392
   PubMed Web of Science ®Google Scholar
• CambauEBonnafousPPeraniESougakoffWJiBJarlierVMolecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosyClin Infect Dis2002341394511731943
   PubMed Web of Science ®Google Scholar
• MaedaSMatsuokaMNakataNMultidrug resistant Mycobacterium leprae from patients with leprosyAntimicrob Agents Chemother200145123635363911709358
   PubMed Web of Science ®Google Scholar
• MatsuokaMKashiwabaraYLiangfenZGotoMKitajimaSA second case of multidrug-resistant Mycobacterium leprae isolated from a Japanese patient with relapsed lepromatous leprosyInt J Lepr Other Mycobact Dis200371324024314608820
   PubMedGoogle Scholar
• GelberRHBalagonVFCellonaRVThe relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not lowInt J Lepr Other Mycobact Dis200472449350015755209
   PubMedGoogle Scholar
• HonradoERTalloVBalisACChanGPChoSNNoncompliance with the world health organization-multidrug therapy among leprosy patients in Cebu, Philippines: its causes and implications on the leprosy control programDermatol Clin200826222122918346553
   PubMed Web of Science ®Google Scholar
• CellonaRVBalagonMFdela CruzECLong-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patientsInt J Lepr Other Mycobact Dis200371430831914763888
   PubMedGoogle Scholar
• GirdharBKGirdharAKumarARelapses in multibacillary leprosy patients: effect of length of therapyLepr Rev200071214415310920610
   PubMed Web of Science ®Google Scholar
• NormanGJosephGRichardJRelapses in multibacillary patients treated with multi-drug therapy until smear negativity: findings after twenty yearsInt J Lepr Other Mycobact Dis20047211715217321
   PubMedGoogle Scholar
• MalathiMThappaDMFixed-duration therapy in leprosy: limitations and opportunitiesIndian J Dermatol20135829310023716796
   PubMedGoogle Scholar
• RajuMSJohnASKuipersPWhat stops people completing multi-drug therapy? Ranked perspectives of people with leprosy, their head of family and neighbours – across four Indian statesLepr Rev201586162026065144
   PubMed Web of Science ®Google Scholar
• JiBGrossetJCombination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosyLepr Rev2000Suppl 71S81S8711201894
   PubMed Web of Science ®Google Scholar
• JiBJametPPeraniEGBactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patientsAntimicrob Agents Chemother1996409213721418878595
   PubMed Web of Science ®Google Scholar
• ChanGPGarcia-IgnacioBYChavezVEClinical trial of clarithromycin for lepromatous leprosyAntimicrob Agents Chemother19943835155178203847
   PubMed Web of Science ®Google Scholar
• CostaMBCavalcanti NetoPFMartelliCMDistinct histopathological patterns in single lesion leprosy patients treated with single dose therapy (ROM) in the Brazilian Multicentric StudyInt J Lepr Other Mycobact Dis200169317718611875761
   PubMedGoogle Scholar
• FajardoTTJrVillahermosaLGdela CruzECAbalosRMFranzblauSGWalshGPMinocycline in lepromatous leprosyInt J Lepr Other Mycobact Dis19956318177730723
   PubMedGoogle Scholar
• GelberRHMurrayLPSiuPTsangMReaTHEfficacy of minocycline in single dose and at 100 mg twice daily for lepromatous leprosyInt J Lepr Other Mycobact Dis19946245685737868955
   PubMedGoogle Scholar
• GelberRHFukudaKByrdSA clinical trial of minocycline in lepromatous leprosyBMJ1992304681991921737148
   PubMed Web of Science ®Google Scholar
• GrossetJHJiBHGuelpa-LaurasCCPeraniEGN’DeliLNClinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosyInt J Lepr Other Mycobact Dis19905822812952198315
   PubMedGoogle Scholar
• BalagonMFCellonaRVAbalosRMGelberRHSaundersonPRThe efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosyLepr Rev2010811273320496567
   PubMed Web of Science ®Google Scholar
• GelberRHChemotherapy of lepromatous leprosy: recent developments and prospects for the futureEur J Clin Microbiol Infect Dis199413119429527698121
   PubMed Web of Science ®Google Scholar
• GelberRHSiuPTsangMRichardVChehlSKMurrayLPActivity of combinations of dapsone, rifampin, minocycline, clarithromycin, and sparfloxacin against M. leprae-infected miceInt J Lepr Other Mycobact Dis19956322592647602221
   PubMedGoogle Scholar
• JiBGrossetJOfloxacin for the treatment of leprosyActa Leprol1991743213261950440
   PubMedGoogle Scholar
• JiBPeraniEGPetinomCN’DeliLGrossetJHClinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosyAntimicrob Agents Chemother19943846626678031029
   PubMed Web of Science ®Google Scholar
• ConsignySBentouchaABonnafousPGrossetJJiBBactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in miceAntimicrob Agents Chemother200044102919292110991891
   PubMed Web of Science ®Google Scholar
• JiBChauffourAAndriesKJarlierVBactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in miceAntimicrob Agents Chemother20065041558156016569884
   PubMed Web of Science ®Google Scholar
• BurgosJde la CruzEParedesRAndayaCRGelberRHThe activity of several newer antimicrobials against logarithmically multiplying M. leprae in miceLepr Rev201182325325822125933
   PubMed Web of Science ®Google Scholar
• KatochKKatochVMNatrajanM10–12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapyVaccine20042227–283649365715315844
   PubMed Web of Science ®Google Scholar
• NarangTKaurIKumarBRadotraBDDograSComparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosyInt J Lepr Other Mycobact Dis200573210511416830653
   PubMedGoogle Scholar
• BrowneSGSelf-healing leprosy: report on 2749 patientsLepr Rev19744521041114417433
   PubMed Web of Science ®Google Scholar
• EkambaramVSithambaramMSelf-healing in non-lepromatous leprosy in the area of the ELEP Leprosy Control Project Dharmapuri (Tamil Nadu)Lepr India1977493387392592741
   PubMedGoogle Scholar
• BakkerMIHattaMKwenangAPrevention of leprosy using rifampicin as chemoprophylaxisAm J Trop Med Hyg200572444344815827283
   PubMed Web of Science ®Google Scholar
• SmithWCChemoprophylaxis in the prevention of leprosyBMJ2008336764773073118390497
   PubMed Web of Science ®Google Scholar
• MoetFJOskamLFaberRPahanDRichardusJHA study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEPLepr Rev200475437638815682975
   PubMed Web of Science ®Google Scholar
• VijayakumaranPKrishnamurthyPRaoPDeclerqEChemoprophylaxis against leprosy: expectations and methodology of a trialLepr Rev2000Suppl 71S37S40 discussion S–111201885
   PubMed Web of Science ®Google Scholar
• NguyenLNCartelJLGrossetJHChemoprophylaxis of leprosy in the southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 yearsLepr Rev2000Suppl 71S33S35 discussion S5–S611201884
   PubMed Web of Science ®Google Scholar
• DilettoCBlancLLevyLLeprosy chemoprophylaxis in MicronesiaLepr Rev2000Suppl 71S21S33 discussion S4–S511201881
   PubMed Web of Science ®Google Scholar
• SmithCMSmithWCChemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis. MILEP2 Study Group. Mucosal immunology of leprosyJ Infect200041213714211023757
   PubMed Web of Science ®Google Scholar
• TinKPopulation screening and chemoprophylaxis for household contacts of leprosy patients in the Republic of the Marshall IslandsInt J Lepr Other Mycobact Dis199967Suppl 4S26S2910700934
   PubMedGoogle Scholar
• DaulakoECPopulation screening and mass chemoprophylaxis in KiribatiInt J Lepr Other Mycobact Dis1999674 SupplS23S2510700933
   PubMedGoogle Scholar
• MoetFJSchuringRPPahanDOskamLRichardusJHThe prevalence of previously undiagnosed leprosy in the general population of northwest BangladeshPLoS Negl Trop Dis200822e19818301731
   PubMed Web of Science ®Google Scholar
• MoetFJPahanDOskamLRichardusJHCOLEP Study GroupEffectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trialBMJ2008336764776176418332051
   PubMed Web of Science ®Google Scholar
• SetiaMSSteinmausCHoCSRutherfordGWThe role of BCG in prevention of leprosy: a meta-analysisLancet Infect Dis20066316217016500597
   PubMed Web of Science ®Google Scholar
• MerleCSCunhaSSRodriguesLCBCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy controlExpert Rev Vaccines20109220922220109030
   PubMed Web of Science ®Google Scholar
• BehrMAWilsonMAGillWPComparative genomics of BCG vaccines by whole-genome DNA microarrayScience199928454191520152310348738
   PubMed Web of Science ®Google Scholar
• ZodpeySPBansodBSShrikhandeSNMaldhureBRKulkarniSWProtective effect of Bacillus Calmette Guerin (BCG) against leprosy: a population-based case-control study in Nagpur, IndiaLepr Rev199970328729410603718
   PubMed Web of Science ®Google Scholar
• ZodpeySPAmbadekarNNThakurAEffectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Yavatmal District, IndiaPublic Health2005119320921615661132
   PubMed Web of Science ®Google Scholar
• RodriguesLCKerr-PontesLRFrietasMVBarretoMLLong lasting BCG protection against leprosyVaccine20072539–406842684417728023
   PubMed Web of Science ®Google Scholar
• FischerEAde VlasSJHabbemaJDRichardusJHThe long-term effect of current and new interventions on the new case detection of leprosy: a modeling studyPLoS Negl Trop Dis201159e133021949895
   PubMed Web of Science ®Google Scholar
• ConvitJSampsonCZúñigaMImmunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary resultsLancet199233987914464501346818
   PubMed Web of Science ®Google Scholar
• KarongaPreventionTrialGroupRandomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in MalawiLancet1996348901917248691924
   PubMed Web of Science ®Google Scholar
• WHOGlobal tuberculosis programme and global programme on vaccines. Statement on BCG revaccination for the prevention of tuberculosisWkly Epidemiol Rec199570322292317669527
   PubMedGoogle Scholar
• RodriguesLCPereiraSMCunhaSSEffect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trialLancet200536694931290129516214599
   PubMed Web of Science ®Google Scholar
• BarretoMLPereiraSMFerreiraAABCG vaccine: efficacy and indications for vaccination and revaccinationJ Pediatr (Rio J)2006823 SupplS45S5416826312
   PubMedGoogle Scholar
• DüppreNCCamachoLAda CunhaSSEffectiveness of BCG vaccination among leprosy contacts: a cohort studyTrans R Soc Trop Med Hyg2008102763163818514242
   PubMed Web of Science ®Google Scholar
• CunhaSSAlexanderNBarretoMLBCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trialPLoS Negl Trop Dis200822e16718270542
   PubMed Web of Science ®Google Scholar
• van BrakelWCrossHDeclercqEReview of leprosy research evidence (2002–2009) and implications for current policy and practiceLepr Rev201081322827521067065
   PubMed Web of Science ®Google Scholar
• OharaNMatsuokaMNomaguchiHNaitoMYamadaTInhibition of multiplication of Mycobacterium leprae in mouse foot pads by recombinant Bacillus Catmette-Guérin (BCG)Vaccine200018141294129710618524
   PubMed Web of Science ®Google Scholar
• OharaNMatsuokaMNomaguchiHNaitoMYamadaTProtective responses against experimental Mycobacterium leprae infection in mice induced by recombinant Bacillus Calmette-Guerin overproducing three putative protective antigen candidatesVaccine20011915–161906191011228360
   PubMed Web of Science ®Google Scholar
• MakinoMMaedaYIshiiNImmunostimulatory activity of major membrane protein-II from Mycobacterium lepraeCell Immunol20052331536015885677
   PubMed Web of Science ®Google Scholar
• MakinoMMaedaYInagakiKImmunostimulatory activity of recombinant Mycobacterium bovis BCG that secretes major membrane protein II of Mycobacterium lepraeInfect Immun200674116264627117057093
   PubMed Web of Science ®Google Scholar
• GillisTPTulliusMVHorwitzMArBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85BInfect Immun20148293900390925001602
   PubMed Web of Science ®Google Scholar
• GupteMDVallishayeeRSAnantharamanDSComparative leprosy vaccine trial in south IndiaIndian J Lepr199870436938810189587
   PubMedGoogle Scholar
• SreevatsaDesikanKVEvaluation of the efficacy of candidate vaccines against M. leprae infection in miceIndian J Lepr19886022522593192974
   PubMedGoogle Scholar
• BhideMBPradhanKSBapatCVA vaccine from ICRC bacilli against M. leprae infection in mouse foot-padLepr India1978503334344359922
   PubMedGoogle Scholar
• SharmaPMukherjeeRTalwarGPImmunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8–10 yearsLepr Rev200576212714316038246
   PubMed Web of Science ®Google Scholar
• RichardusRAAlamKPahanDFeenstraSGGelukARichardusJHThe combined effect of chemoprophylaxis with single dose rifampicin and immunoprophylaxis with BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: a cluster randomized controlled trial (MALTALEP study)BMC Infect Dis20131345624088534
   PubMed Web of Science ®Google Scholar
• GelberRHBrennanPJHunterSWEffective vaccination of mice against leprosy bacilli with subunits of Mycobacterium lepraeInfect Immun19905837117182407654
   PubMed Web of Science ®Google Scholar
• NgamyingMSawanpanyalertPButrapornREffect of vaccination with refined components of the organism on infection of mice with Mycobacterium lepraeInfect Immun20037131596159812595485
   PubMed Web of Science ®Google Scholar
• BrittonWJMartinEKamathATNeupaneKDRochePWImmunoprophylaxis against Mycobacterium leprae infection with subunit vaccinesLepr Rev2000Suppl 71S176S18111201878
   PubMed Web of Science ®Google Scholar
• RochePWNeupaneKDFailbusSSKamathABrittonWJVaccination with DNA of the Mycobacterium tuberculosis 85B antigen protects mouse foot pad against infection with M. lepraeInt J Lepr Other Mycobact Dis2001692939811757171
   PubMedGoogle Scholar
• NomaguchiHMukaiTTakeshitaFEffect of hsp65 DNA vaccination carrying immunostimulatory DNA sequences (CpG motifs) against Mycobacterium leprae multiplication in miceInt J Lepr Other Mycobact Dis200270318219012483966
   PubMedGoogle Scholar
• GelberRHMehraVBloomBVaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpadsInfect Immun19946210425042557927681
   PubMed Web of Science ®Google Scholar
• NaitoMMatsuokaMOharaNNomaguchiHYamadaTThe antigen 85 complex vaccine against experimental Mycobacterium leprae infection in miceVaccine1999189–1079579810580191
   PubMed Web of Science ®Google Scholar
• NgamyingMVarachitPPhaknilratPLevyLBrennanPJChoSNEffects of vaccination with several mycobacterial proteins and lipoproteins on Mycobacterium leprae infection of the mouseInt J Lepr Other Mycobact Dis2001691434511480318
   PubMedGoogle Scholar
• ColeSTEiglmeierKParkhillJMassive gene decay in the leprosy bacillusNature200140968231007101111234002
   PubMed Web of Science ®Google Scholar
• DuthieMSSampaioLHOliveiraRMDevelopment and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosyVaccine201331581381923228811
   PubMed Web of Science ®Google Scholar
• DuthieMSColerRNLauranceJDProtection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosisInfect Immun20148293979398525024362
   PubMed Web of Science ®Google Scholar
• SchreuderPALibenDSWahjuniSVan Den BroekJDe SoldenhoffRA comparison of Rapid Village Survey and Leprosy Elimination Campaign, detection methods in two districts of East Java, Indonesia, 1997/1998 and 1999/2000Lepr Rev200273436637512549844
   PubMed Web of Science ®Google Scholar
• OskamLSlimEBührer-SékulaSSerology: recent developments, strengths, limitations and prospects: a state of the art overviewLepr Rev200374319620514577464
   PubMed Web of Science ®Google Scholar
• ReeceSTIretonGMohamathRML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosyClin Vaccine Immunol200613333334016522774
   PubMedGoogle Scholar
• DuthieMSGotoWIretonGCUse of protein antigens for early serological diagnosis of leprosyClin Vaccine Immunol200714111400140817898185
   PubMed Web of Science ®Google Scholar
• SampaioLHStefaniMMOliveiraRMImmunologically reactive M. leprae antigens with relevance to diagnosis and vaccine developmentBMC Infect Dis2011112621269435
   PubMed Web of Science ®Google Scholar
• HungriaEMde OliveiraRMde SouzaALSeroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in BrazilMem Inst Oswaldo Cruz2012107Suppl 110411123283461
   PubMed Web of Science ®Google Scholar
• GelukADuthieMSSpencerJSPostgenomic Mycobacterium leprae antigens for cellular and serological diagnosis of M. leprae exposure, infection and leprosy diseaseLepr Rev201182440242122439280
   PubMed Web of Science ®Google Scholar
• MillerRAGorderDHarnischJPAntibodies to phenolic glycolipid-I during long-term therapy: serial measurements in individual patientsInt J Lepr Other Mycobact Dis19875546336363323367
   PubMedGoogle Scholar
• ChanteauSCartelJLCelerierPPlichartRDesforgesSRouxJPGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapyInt J Lepr Other Mycobact Dis19895747357432681456
   PubMedGoogle Scholar
• MeekerHCSchuller-LevisGFuscoFGiardina-BecketMASersenELevisWRSequential monitoring of leprosy patients with serum antibody levels to phenolic glycolipid-I, a synthetic analog of phenolic glycolipid-I, and mycobacterial lipoarabinomannanInt J Lepr Other Mycobact Dis19905835035112205685
   PubMedGoogle Scholar
• PrakashKSehgalVNAggarwalREvaluation of phenolic glycolipid-I (PGL-I) antibody as a multidrug therapy (MDT) monitorJ Dermatol199320116208482747
   PubMedGoogle Scholar
• RadaEUlrichMAranzazuNA follow-up study of multibacillary Hansen’s disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT)Int J Lepr Other Mycobact Dis19976533203279401484
   PubMedGoogle Scholar
• ChoSNCellonaRVVillahermosaLGDetection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapyClin Diagn Lab Immunol20018113814211139208
   PubMedGoogle Scholar
• RochePWBrittonWJFailbusSSNeupaneKDTheuvenetWJSerological monitoring of the response to chemotherapy in leprosy patientsInt J Lepr Other Mycobact Dis199361135438326179
   PubMedGoogle Scholar
• DrowartAChanteauSHuygenKEffects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patientsInt J Lepr Other Mycobact Dis199361129348326178
   PubMedGoogle Scholar
• DuthieMSHayMNRadaEMSpecific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markersEur J Clin Microbiol Infect Dis201130101257126521544695
   PubMed Web of Science ®Google Scholar
• DuthieMSOrculloFMAbbelanaJMaghanoyABalagonMFComparative evaluation of antibody detection tests to facilitate the diagnosis of multibacillary leprosyAppl Microbiol Biotechnol201610073267327526820649
   PubMed Web of Science ®Google Scholar
• DuthieMSRaychaudhuriRTutterrowYLA rapid ELISA for the diagnosis of MB leprosy based on complementary detection of antibodies against a novel protein-glycolipid conjugateDiagn Microbiol Infect Dis201479223323924666703
   PubMed Web of Science ®Google Scholar
• DuthieMSBalagonMFMaghanoyARapid quantitative serological test for detection of infection with Mycobacterium leprae, the causative agent of leprosyJ Clin Microbiol201452261361924478496
   PubMed Web of Science ®Google Scholar
• CardosoLPDiasRFFreitasAADevelopment of a quantitative rapid diagnostic test for multibacillary leprosy using smart phone technologyBMC Infect Dis201313149724152601
   PubMed Web of Science ®Google Scholar
• FreitasAAOliveiraRMHungriaEMAlterations to antigen-specific immune responses before and after multidrug therapy of leprosyDiagn Microbiol Infect Dis201583215416126233487
   PubMed Web of Science ®Google Scholar
• RadaEDuthieMSReedSGAranzazuNConvitJSerologic follow-up of IgG responses against recombinant mycobacterial proteins ML0405, ML2331 and LID-1 in a leprosy hyperendemic area of VenezuelaMem Inst Oswaldo Cruz2012107Suppl 1909423283459
   PubMed Web of Science ®Google Scholar
• StefaniMMGuerraJGSousaALPotential plasma markers of type 1 and type 2 leprosy reactions: a preliminary reportBMC Infect Dis2009917519473542
   PubMed Web of Science ®Google Scholar
• DuthieMSGotoWIretonGCAntigen-specific T-cell responses of leprosy patientsClin Vaccine Immunol200815111659166518784342
   PubMedGoogle Scholar
• SampaioLHSousaALBarcelosMCReedSGStefaniMMDuthieMSEvaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosyEur J Clin Microbiol Infect Dis20123171443145122076550
   PubMed Web of Science ®Google Scholar
• OliveiraRMHungriaEMde Araújo FreitasASynergistic antigen combinations for the development of interferon gamma release assays for paucibacillary leprosyEur J Clin Microbiol Infect Dis20143381415142424619112
   PubMed Web of Science ®Google Scholar
• GelukABiomarkers for leprosy: would you prefer T (cells)?Lepr Rev201384131223741878
   PubMed Web of Science ®Google Scholar
• BoboshaKTangSTvan der Ploeg-van SchipJJMycobacterium leprae virulence-associated peptides are indicators of exposure to M. leprae in Brazil, Ethiopia and NepalMem Inst Oswaldo Cruz2012107Suppl 111212323283462
   PubMed Web of Science ®Google Scholar